Contact Information: Contacts: James E. Fickenscher Chief Financial Officer Auxilium Pharmaceuticals, Inc. (484) 321-5900 Fern Lazar Lazar Partners, Ltd. (212) 867-1765
Auxilium Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
| Source: Auxilium Pharmaceuticals, Inc.
MALVERN, PA--(Marketwire - January 29, 2008) - Auxilium Pharmaceuticals (NASDAQ : AUXL ) today
announced that Mr. Armando Anido, Chief Executive Officer and President,
and Mr. Jim Fickenscher, Chief Financial Officer, will participate in the
Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device
Conference to be held February 5 through February 7, 2008 at The Grand
Hyatt Hotel in New York City. Mr. Anido is scheduled to present an overview
of the Company and its product pipeline at 2:20 p.m. Eastern Time on
Tuesday, February 5, 2008.
To listen to the audio web cast of the presentation during or after the
event, please visit: http://www.auxilium.com. The replay will be available
for fourteen days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets Testim®
1%, a topical testosterone gel, for the treatment of hypogonadism through
its approximately 190-person sales and marketing team. Auxilium has four
projects in clinical development. XIAFLEX (clostridial collagenase for
injection), formerly referred to as AA4500, is in phase III of development
for the treatment of Dupuytren's contracture and is in phase II of
development for the treatment of Peyronie's disease and Frozen Shoulder
syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product
candidate for the treatment of overactive bladder (AA4010) is in phase I of
development. The Company is currently seeking a partner to further develop
this product candidate. Auxilium has two pain products using its
transmucosal film delivery system in pre-clinical development. Auxilium has
rights to six additional pain products and products for hormone replacement
and urologic disease using its transmucosal film delivery system. Auxilium
also has options to all indications using XIAFLEX for non-topical
formulations. For additional information, visit http://www.auxilium.com.
SAFE HARBOR STATEMENT
This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the 2008 Merrill Lynch
Global Pharmaceutical, Biotechnology and Medical Device Conference, and the
Company's products in development for Dupuytren's contracture, Peyronie's
disease, Frozen Shoulder syndrome, overactive bladder, pain, hormone
replacement and urologic disease. All statements other than statements of
historical facts contained in this release, including but not limited to,
statements regarding future expectations, plans and prospects for the
Company, statements regarding forward-looking financial information and
other statements containing the words "believe," "may," "could," "will,"
"estimate," "continue," "anticipate," "intend," "should," "plan," "expect,"
and similar expressions, as they relate to the Company, constitute
forward-looking statements. Actual results may differ materially from those
reflected in these forward-looking statements due to various factors,
including general financial, economic, regulatory and political conditions
affecting the biotechnology and pharmaceutical industries and those
discussed in the Company's Annual Report on Form 10-K for the year ended
December 31, 2006 and in the Company's Quarterly Report on Form 10-Q for
the period ended September 30, 2007 under the heading "Risk Factors," which
are on file with the Securities and Exchange Commission (the "SEC") and may
be accessed electronically by means of the SEC's home page on the Internet
at http://www.sec.gov or by means of the Company's home page on the
Internet at http://www.auxilium.com under the heading "Investor Relations
-- SEC Filings." There may be additional risks that the Company does not
presently know or that the Company currently believes are immaterial which
could also cause actual results to differ from those contained in the
forward-looking statements. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements.
In addition, forward-looking statements provide the Company's expectations,
plans or forecasts of future events and views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company's assessments to change. However, while the Company
may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company's assessments as of any date subsequent to the date of this
release.